NCT00853554已完成1 期
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Hydromorphone Hydrochloride (8 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (DILAUDID®, 8 mg Tablet, Knoll Pharmaceutical Company) in Normal Human Subjects Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mallinckrodt
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Bioequivalence based on AUCt, AUCinf and Cmax
研究概览
简要总结
The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of hydromorphone 8 mg to an equivalent oral dose of a commercially available hydromorphone tablet (DILAUDID® 8 mg, Knoll Pharmaceutical Company) in a test group of healthy subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males or non-pregnant, non-lactating females, 18 years of age or older.
- •Female subjects must be postmenopausal for at least one year, or surgically sterile, or practicing adequate non-hormonal contraception for at least 3 months prior to and for the duration of study participation. All female subjects will undergo a pregnancy test at screening and at check-in to the clinical study site for every dosing period. The results of the test must be negative for continued participation.
- •Weight must be within 15% of the ideal weight for height and frame, as adopted by the Metropolitan Life Insurance Co.,
- •Qualifying subjects must be in good health and physical condition as determined by a screening medical history obtained within 30 days prior to study start. Subjects should not present with a history of significant past illness expected to affect the investigation.
- •The normal status of subjects will be confirmed by the following procedures:
- •Laboratory tests (serum chemistry, hematology, urinalysis)
- •Human immunodeficiency virus (HIV), hepatitis, alcohol, and "drugs of abuse" testing will be done at screening. Results of the HIV, hepatitis, alcohol, and "drugs of abuse" tests must be negative or non-reactive for
- •Electrocardiogram: A 12-lead electrocardiogram (ECG) will be obtained for all subjects. This ECG must be interpreted by appropriately trained and experienced medical personnel. A subject with an ECG that is not within normal range does not qualify, unless specifically accepted (with comment) by the investigator.
- •Subjects must be able to provide written consent and agree to abide by the study requirements.
排除标准
- •History of alcohol, drug, or narcotic abuse or dependence.
- •Chronic use of tranquilizers, sedatives, aspirin, antibiotics, or other medications.
- •History or presence of major organ dysfunction.
- •History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorder capable of altering the absorption, metabolism, or elimination of drugs or constituting a risk factor when taking hydromorphone.
- •History of anxiety, tension, severe agitation, psychosis, or mental depression.
- •Family history or diagnosis of epilepsy or other seizure disorder.
- •History of acute abdominal conditions.
- •History of conditions that might contraindicate or require caution be used in the administration of hydromorphone including: renal impairment, hepatobiliary or pancreatic disease, GI obstruction, cardiac disease, obstructive pulmonary disease, acute or severe bronchial asthma, hypercarbia, elevated intracranial pressure, depleted blood volume, paralytic ileus, or allergy to hydromorphone, any opiate agonists, or naltrexone.
- •Administration of any other investigational drug during the 30 days prior to enrollment into the study.
- •Subjects who smoke or have a history of smoking, or use nicotine-containing products.
- •Subjects who have donated blood within 30 days prior to study entry, including that withdrawn during the conduct of any other clinical study.
- •Subjects presenting with acute illness.
- •Subjects who have taken prescription drugs within 14 days or over-the-counter medications (including herbal preparations) within 7 days prior to dosing except for standard daily dose multivitamins.
研究组 & 干预措施
A
Experimental
Hydromorphone Hydrochloride tablet 8 mg
干预措施: Hydromorphone Hydrochloride tablet 8 mg (Drug)
B
Active Comparator
Dilaudid® tablet 8 mg
干预措施: Dilaudid® tablet 8 mg (Drug)
结局指标
主要结局
Bioequivalence based on AUCt, AUCinf and Cmax
时间窗: Two-period crossover with blood samples obtained prior to and following each dose at selected times through 24 hours. Washout period between doses was 7 days.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg TabletsHealthyNCT00853216Mallinckrodt38
已完成
1 期
Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg TabletsHealthyNCT00853736Mallinckrodt23
已完成
1 期
Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg TabletsHealthyNCT00853320Mallinckrodt38
已完成
1 期
Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg TabletsHealthyNCT00853892Mallinckrodt34
已完成
1 期
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral SuspensionHealthyNCT00853190Mallinckrodt43